Partners Announced for Texas Ibogaine Research Consortium Funding
In a historic move that positions Texas at the forefront of next-generation psychedelic medicine and research, the Texas Health and Human Services Commission (HHSC) has officially awarded $50 million to a collective of public universities across the state to establish the Texas Ibogaine Research Consortium. The funding, authorized by the state legislature after last year’s passage of the Texas Ibogaine Initiative, will launch a comprehensive, statewide clinical trial initiative known as Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma (IMPACT).
The two-year, multicenter project aims to evaluate the safety and efficacy of ibogaine – a powerful psychoactive alkaloid derived from the West African iboga shrub – in treating some of the state’s most pressing behavioral health challenges, including opioid dependency and traumatic brain injury (TBI).
A Statewide Scientific Alliance
The IMPACT initiative will be co-led by UTHealth Houston and the University of Texas Medical Branch at Galveston (UTMB). The consortium brings together a unprecedented collection of the state’s premier academic and medical institutions to conduct what psychedelic advocates in Texas describe as the most significant state-funded study of a Schedule I substance in U.S. history.
Under the leadership of UTHealth Houston and UTMB, the consortium will operate through specialized research tracks designed to address specific public health crises. One primary branch, led by UTHealth Houston and its partners, will focus on the potential for ibogaine to interrupt opioid use disorder and alleviate chronic addiction patterns.
Simultaneously, the McGill Center for Psychedelic Research and Therapy at Dell Medical School and the Baylor College of Medicine will spearhead investigations into how the substance may benefit veterans and first responders suffering from traumatic brain injuries and associated PTSD. This collaborative effort is further bolstered by the participation of Texas Tech University, Texas A&M University, and the University of North Texas, collectively establishing a robust statewide infrastructure aimed at meeting the rigorous clinical standards required for eventual U.S. Food and Drug Administration (FDA) approval.
“This landmark clinical trial reflects our unwavering commitment to advancing research that improves lives and delivers the highest standards of care,” said Dr. Melina Kibbe, president of UTHealth Houston in a press release following the funding and partnership announcement. “By joining forces with outstanding partners across our state, we are building on Texas’ tradition of innovation to ensure patients struggling with addiction and behavioral health conditions have access to the best possible outcomes.”
Legislative Momentum and the “Texas Model”
The creation of the consortium was mandated by Senate Bill 2308, which was signed into law in June 2025 by Governor Greg Abbott. The bill allocated $50 million in state matching funds, requiring the consortium to secure private investment to double the research budget – a public-private partnership model designed to accelerate drug development while protecting taxpayer interests.
State Senator Tan Parker, a primary sponsor of the legislation, emphasized the necessity of a rigorous, evidence-based approach.
“Texas has a responsibility to pursue solutions that are driven by evidence, compassion, and accountability,” said Parker in a press release in December 2025. “This landmark clinical trial ensures that ibogaine is studied through the highest scientific and medical standards, with patient safety at the forefront.”
Political support for the initiative has been notably bipartisan, often championed by advocates for veterans’ rights. Former Texas Governor Rick Perry has been a vocal proponent of the research, frequently citing the success stories of veterans who sought ibogaine treatment outside the U.S. after traditional therapies failed to address their “invisible wounds.”
Redefining Mental Health Care
For many in the psychedelic research community, the scale of the IMPACT initiative marks a turning point in how state governments approach the mental health crisis. Logan Davidson, Senior Advisor and Policy Director for the nonprofit advocacy group Texans for Greater Mental Health (T4GMH), described the announcement as an “extraordinary milestone.”
“It’s remarkable to see so many institutions across the state – public universities, medical schools, and health systems – now stepping into this work together,” said Davidson in an statement for Lucid News. “Texas is redefining what’s possible when we confront our mental health crisis with urgency, collaboration, and science. The fresh expertise from the UT, UNT, Texas Tech, and Texas A&M systems will accelerate innovation in a way we haven’t seen before.”
The Advocacy Tension: Innovation vs. Criminalization
Despite the enthusiasm within the medical and legislative communities, the announcement has also sparked a critical dialogue regarding drug policy and equity. While the state is investing millions into the medicalization of ibogaine, the substance remains a Schedule I controlled substance under federal and state law, meaning possession outside of these sanctioned trials can still lead to incarceration.
Ceejay Blake, a prominent Houston-based grassroots psychedelic activist and Community Leader for the Psychedelic Society of Texas, called the funding a “meaningful step toward evidence-based care,” but was quick to point out the inherent contradictions in the state’s approach.
“It’s important to name the tension between publicly funded innovation and the continued criminalization of the very substances – and people – who paved the way for this knowledge,” Blake told Lucid News.
Blake, who co-founded the Houston-based Meroë Moto Wellness Collective as part of her efforts to blend harm reduction with meaningful cultural engagement, noted that the benefits of this research may not reach the communities most harmed by the “War on Drugs.”
“Funding ibogaine research while continuing to criminalize people – especially Black, Indigenous, and low-income communities – for the same substances exposes a deep contradiction,” Blake said. “If this initiative is truly about healing rather than selective access, it must address these disparities. Any true progress must include pathways to access and repair for those still incarcerated or facing severe punishment for psychedelics, not just future FDA approvals.”
Texas Cannabis Community Offers Cautionary Tales
For her part, Blake isn’t the only drug policy activist in Texas speaking out about next steps on the road to real reform; advocacy veterans of the state’s drug policy battles are also warning their contemporaries that the transition from funding to implementation requires rigorous community oversight. Jeannette McKenzie, Director of People for the Texas Cannabis Collective, emphasizes that the success of such initiatives depends heavily on maintaining an ethical and inclusive framework throughout the research process.
Drawing parallels to recent legislative victories, McKenzie noted that grassroots pressure was instrumental in defeating several proposed Hemp-Derived THC bans during the last session. She argues that this same “people power” must now be applied to the rollout of psychedelic research. “The success we’ve seen with the Texas Ibogaine Initiative has been groundbreaking, but there will still be plenty of challenges ahead in ensuring the funding is properly used both ethically and effectively,” said McKenzie in a statement provided to Lucid News.
According to McKenzie, the primary lesson from the cannabis advocacy front is the necessity of “just showing up” and maintaining a consistent presence in policy discussions. She advocates for a collaborative model that integrates the perspectives of small businesses, patients, and healthcare providers to ensure the state’s research agenda remains accountable to the public. As the consortium begins its work, McKenzie insists that the collective pressure from a diverse coalition of stakeholders is the only way to ensure that psychedelic treatments are developed with the entire community’s needs in mind. “With something as important and exciting as psychedelic treatment, it’s vital that we ensure all perspectives are considered by engaging the entire community in our conversations at every level,” she added.
Looking Toward the Future
The long-term goal of the IMPACT consortium is to provide the clinical data necessary for the FDA to reclassify ibogaine as an approved prescription medicine. Currently, thousands of Americans travel to clinics in Mexico, Costa Rica, and Europe to access ibogaine, often paying tens of thousands of dollars for treatments that lack standardized medical oversight.
By bringing these trials to Texas soil, the consortium hopes to establish a domestic “center of excellence” for psychedelic medicine. The research will not only focus on the psychoactive effects of the drug but will also include intensive cardiac monitoring, as ibogaine is known to carry risks of heart arrhythmia if not administered under strict medical supervision.
As the trials begin, the eyes of the nation will likely remain on the Lone Star State. If successful, the Texas Ibogaine Research Consortium could provide the blueprint for how other states – and eventually the federal government – integrate indigenous plant medicines into the modern psychiatric toolkit.
For now, the project reflects a unique Texan alliance: one where conservative lawmakers, elite medical researchers, and grassroots advocates are all looking toward a once-taboo shrub from Africa as a potential answer to a modern American tragedy of absent and ineffective mental health care.